Perioperative camrelizumab and apatinib combined with chemotherapy for locally advanced gastric cancer in China: three-year survival outcomes of phase 2 randomized controlled trialResearch in context

Summary: Background: The Arise-FJ-G005 study compared the efficacy and safety of perioperative camrelizumab and apatinib combined with chemotherapy with those of perioperative chemotherapy alone for locally advanced gastric cancer (LAGC) and assessed its effect on major pathological response (MPR)....

Descripció completa

Dades bibliogràfiques

Autors principals:	Jian-Xian Lin, Ze-Ning Huang, Yi-Hui Tang, Kai Ye, Zhen-Fa Wang, Li-Sheng Cai, Wei Lin, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Qi-Yue Chen, Long-Long Cao, Chao-Hui Zheng, Chang-Ming Huang
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-11-01
Col·lecció:	EClinicalMedicine
Matèries:	Gastric cancer Neoadjuvant therapy Immunotherapy Antiangiogenic therapy Survival Randomized controlled trial
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2589537025005012
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!